Spero Therapeutics
Multi-Asset, clinical-stage biopharmaceutical company focused on multidrug-resistant bacterial infections.
Market cap
$165m
Enterprise value
$120m
Share price
$2.90 SPRO
loading funding rounds…
Atlas Venture(exited)
Lundbeckfonden Ventures(exited)
CARB-X(exited)
GV(exited)
RA Capital Management(exited)
Rock Springs Capital(exited)
SR One(exited)
The Kraft Group(exited)
Osage University Partners(exited)
Partners Innovation Fund(exited)
Atlas Peak Capital(exited)
US Department of Defense(exited)
Novo Holdings(exited)
Lundbeckfonden(exited)
HealthCare Royalty(exited)
MRL Ventures(exited)
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 200 % | 58 % | 97 % | 96 % | 166 % | 99 % | (72 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1413 %) | (1333 %) | (848 %) | (479 %) | (39 %) | 32 % | (261 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1389 %) | (1285 %) | (839 %) | (492 %) | (96 %) | 24 % | (250 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1130 % | 1387 % | 718 % | 353 % | 98 % | 53 % | 353 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.